{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:49:40Z","timestamp":1789523380145,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"The University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ijantimicag.2025.107579","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T16:34:43Z","timestamp":1753202083000},"page":"107579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Attitudes to phage therapy among Australian infectious diseases physicians"],"prefix":"10.1016","volume":"66","author":[{"given":"Martin","family":"Plymoth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6141-4093","authenticated-orcid":false,"given":"Stephanie A.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9114-6694","authenticated-orcid":false,"given":"Ameneh","family":"Khatami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-8616","authenticated-orcid":false,"given":"Holly A.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Sacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4163-511X","authenticated-orcid":false,"given":"Ruby CY.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Iredell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2025.107579_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1057\/s41599-020-0478-4","article-title":"Phage therapy as a potential solution in the fight against AMR: obstacles and possible futures","volume":"6","author":"Brives","year":"2020","journal-title":"Palgrave Commun"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1250848","article-title":"Regulations of phage therapy across the world","volume":"14","author":"Yang","year":"2023","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0003","series-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","first-page":"629","volume":"399","year":"2022"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0004","unstructured":"O'Neill J. Tackling drug-resistant infections globally: Final report and recommendations. London: Review on Antimicrobial Resistance; 2016. Accessed 8th August 2024. Available from: https:\/\/amr-review.org."},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0005","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02071-21","article-title":"Considerations for the use of phage therapy in clinical practice","volume":"66","author":"Suh","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0006","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1071\/MA19004","article-title":"The future of phage clinical trials in Australia","volume":"40","author":"Potent","year":"2019","journal-title":"Microbiol Aust"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0007","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41564-019-0634-z","article-title":"Safety of bacteriophage therapy in severe Staphylococcus aureus infection","volume":"5","author":"Petrovic Fabijan","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-065401","article-title":"Standardised treatment and monitoring protocol to assess safety and tolerability of bacteriophage therapy for adult and paediatric patients (STAMP study): protocol for an open-label, single-arm trial","volume":"12","author":"Khatami","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0009","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1093\/cid\/ciad497","article-title":"Therapeutic phage monitoring: a review","volume":"77","author":"Bosco","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243947","article-title":"Patient perceptions of phage therapy for diabetic foot infection","volume":"15","author":"Macdonald","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0285824","article-title":"Phage therapy and the public: increasing awareness essential to widespread use","volume":"18","author":"McCammon","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1490737","article-title":"Perception of phage therapy and research across selected professional and social groups in Poland","volume":"13","author":"\u017baczek","year":"2025","journal-title":"Front Public Health"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0013","unstructured":"Australian Government Department of Health. Physician 2016 Factsheet. 2016. Accessed 6th June 2024. Available from https:\/\/hwd.health.gov.au"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0014","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9030596","article-title":"Phage therapy for Mycobacterium abscessus and strategies to improve outcomes","volume":"9","author":"Hashemi Shahraki","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0016","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3947\/ic.2023.0067","article-title":"Phage therapy in Korea: a prescribers\u2019 Survey of attitudes amongst Korean infectious diseases specialists towards Phage therapy","volume":"56","author":"Lee","year":"2024","journal-title":"Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0294190","article-title":"Phage therapy: awareness and demand among clinicians in the United Kingdom","volume":"18","author":"Simpson","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0018","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3389\/fimmu.2020.00303","article-title":"The rise of non-tuberculosis mycobacterial lung disease","volume":"11","author":"Ratnatunga","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0019","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40101-021-00269-7","article-title":"The determinants of survival among adults with cystic fibrosis-a cohort study","volume":"40","author":"Durda-Masny","year":"2021","journal-title":"J Physiol Anthropol"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0020","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12941-020-00389-5","article-title":"Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review","volume":"19","author":"Chegini","year":"2020","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0021","article-title":"Disease burden, associated mortality and economic impact of antimicrobial resistant infections in Australia","volume":"27","author":"Wozniak","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/v13061182","article-title":"Successful treatment of Staphylococcus aureus prosthetic joint infection with bacteriophage therapy","volume":"13","author":"Ramirez-Sanchez","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0023","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1302\/2058-5241.6.210073","article-title":"A systematic review of phage therapy applied to bone and joint infections: an analysis of success rates, treatment modalities and safety","volume":"6","author":"Genevi\u00e8re","year":"2021","journal-title":"EFORT Open Rev"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0024","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3389\/fmicb.2020.01161","article-title":"Good manufacturing practice (GMP) compliance for phage therapy medicinal products","volume":"11","author":"Bretaudeau","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0025","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.copbio.2020.12.018","article-title":"Phage Biobank: present challenges and future perspectives","volume":"68","author":"Lin","year":"2021","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0026","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.1038\/s41598-023-36034-2","article-title":"Combination of genetically diverse Pseudomonas phages enhances the cocktail efficiency against bacteria","volume":"13","author":"Naknaen","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0027","doi-asserted-by":"crossref","first-page":"uqae003","DOI":"10.1093\/femsml\/uqae003","article-title":"Multireceptor phage cocktail against Salmonella enterica to circumvent phage resistance","volume":"5","author":"Martinez-Soto","year":"2024","journal-title":"Microlife"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0028","doi-asserted-by":"crossref","first-page":"431","DOI":"10.5694\/mja2.50810","article-title":"COVID-19 response: the perspectives of infectious diseases physicians and clinical microbiologists","volume":"213","author":"Foley","year":"2020","journal-title":"Med J Aust"},{"key":"10.1016\/j.ijantimicag.2025.107579_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/v15020588","article-title":"Phage therapy in Germany-update 2023","volume":"15","author":"Willy","year":"2023","journal-title":"Viruses"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925001347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925001347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:34:54Z","timestamp":1789223694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857925001347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0924857925001347"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107579","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.07.03.23292153","asserted-by":"object"}]},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Attitudes to phage therapy among Australian infectious diseases physicians","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107579","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107579"}}